CLSDQ (Clearside Biomedical) Moat Score: 4/10 (As of Jul. 06, 2026)


CLSDQ Clearside Biomedical Inc CLSDQ
49 GF Score
Price $0.13
GF Value $6.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Moat Score?

Clearside Biomedical CLSDQ 49 Moat Score is 4 as of Jul. 06, 2026. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,395 Biotechnology companies, Clearside Biomedical ranks better than 88.75% on this metric.

Clearside Biomedical has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Clearside Biomedical has Narrow Moat: Clearside Biomedical Inc has some valuable intellectual property and regulatory barriers in the biotech sector. However, its market share is limited, and it lacks strong brand strength or customer loyalty, making its moat modest.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Clearside Biomedical might have Narrow Moat - Discernible but modest moat.

Clearside Biomedical  (OTCPK:CLSDQ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Clearside Biomedical Moat Score Related Terms

CLSDQ vs LYRA, EVFM, ATXI: Moat Score Comparison

For the Biotechnology subindustry, Clearside Biomedical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Moat Score distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Moat Score falls into.


CLSDQ
49GF Score
Clearside Biomedical Inc CLSDQ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Clearside Biomedical (CLSDQ) has a Moat Score of 4 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Clearside Biomedical ranks #157 out of 1395 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Clearside Biomedical's Moat Score too high?
Clearside Biomedical's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Clearside Biomedical's value of 4 is 100% above this industry median. Based on the distribution chart, Clearside Biomedical ranks #157 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Moat Score compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #157 out of 1395 companies for Moat Score. This places Clearside Biomedical in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Clearside Biomedical's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearside Biomedical's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current Moat Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • Moat Score: 4
  • GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
  • GF Score™: 49/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1395)

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for CLSDQ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$6.34
GF Value